SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY

Data ReadoutSLS009Positive

AI Analysis

Summary

Sellas Life Sciences' stock recovered from a 2-day decline as its SLS009 AML trial receives attention for combining drugs from major pharma companies AbbVie, Roche, and Bristol Myers Squibb.

Clinical Trial Data

Importance:4/10

Sentiment:

0.30

clinical_trialAMLdrug_combinationstock_movement

Related Companies

$SLS $ABBV $RHHBY $BMY

Read the original article

Published by yahoo_finance on July 9, 2026 4:38 AM

Read Original